Do Omega-3 Fish Oil Supplements Work? What the Large Trials Found

This article is part of Supplement Science Explained, a Learning Hub collection on how common supplements work and what the research does and does not show.

Quick answer: The honest answer is that it depends on what you are asking fish oil to do. In the largest pooled analyses, which together included well over 100,000 people, ordinary doses of omega-3 supplements made little or no difference to overall death rates, strokes, or total cardiovascular events, although some analyses found a small reduction in heart attacks and coronary heart disease events. Higher doses of about 3 grams a day of EPA and DHA lowered blood triglycerides by roughly 15 to 27 percent in controlled studies, and blood pressure fell by a small amount, around 2 to 3 points on the top number. Higher doses were also linked with a greater chance of atrial fibrillation, an irregular heart rhythm, in people who already had high cardiovascular risk. For most people, eating oily fish regularly is the simplest starting point, and a supplement is a decision worth making with a clinician who knows your health history and medicines.

Taking a lot of supplements and not sure what's worth it?

Send me your list for a free supplement review. There is no cost and no appointment needed.

Get my free supplement review

Key takeaways

EPA and DHA are the long-chain omega-3 fats found mainly in oily fish. They become part of cell membranes, including the membranes of red blood cells, heart cells, and platelets, which is why researchers measure them as an Omega-3 Index. Plant omega-3, called ALA, is a different fat that the body converts only in small amounts.

In VITAL, which followed 25,871 adults for a median of 5.3 years, 1 gram a day of fish oil did not significantly lower major cardiovascular events (hazard ratio 0.92, 95 percent confidence interval 0.80 to 1.06) or cancer (hazard ratio 1.03), although heart attacks were 28 percent lower in the fish oil group.

A Cochrane review of 86 trials and 162,796 people found high-certainty evidence of little or no effect on all-cause death or cardiovascular events, but low-certainty evidence of a small reduction in coronary heart disease events (risk ratio 0.91) and a reliable reduction in triglycerides of about 15 percent.

A 2022 meta-analysis of 71 trials found that a combined 2 to 3 grams a day of EPA and DHA lowered systolic blood pressure by about 2.6 points on average, with larger effects in people who already had high blood pressure or high blood lipids.

A 2026 meta-analysis of 35 trials found that high-dose EPA and DHA, above 1,500 milligrams a day, was linked to a 43 percent higher odds of new atrial fibrillation, but only in people at high cardiovascular risk. Lower doses and lower-risk groups showed no significant increase.

In a randomized trial of 1,516 people having heart surgery, fish oil did not increase major bleeding (odds ratio 0.81), which challenges the long-standing advice to stop it before every procedure. Still, anyone planning surgery or taking blood thinners should ask their own clinician.

Why fish oil is so confusing

Few supplements have been studied as heavily as fish oil, and few have produced such mixed headlines. Some years it is described as a heart-protective staple, and the next year a large trial reports that it did nothing. Both of those stories can be true at once, because the studies asked different questions of different people using different doses, different products, and different timelines.

In this article I want to separate those questions. I will explain what the omega-3 fats EPA and DHA actually do inside the body, walk through the largest trials and pooled analyses with their real numbers, look at what the research shows for triglycerides and blood pressure, and then cover safety, interactions, and the limits of what we can conclude. If you have read my article on the Omega-3 Index blood test, this piece is the supplement-focused companion, and my guide on who should consider omega-3s covers the practical side.

What EPA and DHA are and what they do in the body

The term omega-3 covers a family of fats. The two that matter most in the fish oil conversation are eicosapentaenoic acid, or EPA, and docosahexaenoic acid, or DHA. Both are long-chain fats found mainly in oily fish and other seafood, and some algae also make them. A third omega-3, alpha-linolenic acid or ALA, comes from plant foods such as flaxseed and walnuts. The Cochrane review I discuss below evaluated these two groups separately, because trials of plant ALA and trials of fish-derived EPA and DHA are not testing the same thing.

Once EPA and DHA are absorbed, they are built into the phospholipids that make up cell membranes. That changes how the membrane behaves and which signaling molecules the cell can make. In platelets, for example, EPA and DHA may compete with the omega-6 fat arachidonic acid for a place in the membrane and for the enzymes that convert it into signaling compounds, including thromboxane A2, which encourages platelets to clump. Replacing some of that arachidonic acid with EPA changes the mix of compounds that are produced, which is one reason researchers have studied omega-3 intake in relation to clotting and inflammation. Researchers have also described effects on heart rate, because omega-3 intake has been associated with a slower resting heart rate through increased vagal tone, even at modest intakes of about 500 milligrams a day.

Because EPA and DHA end up in cell membranes, they can be measured in the blood. The most standardized method measures them in red blood cells and expresses the result as the Omega-3 Index, which is EPA plus DHA as a percentage of the fatty acids in the red blood cell membrane. A review of this test by Dr. Clemens von Schacky notes that the Omega-3 Index was defined in 2004 and that typical values in the United States have been reported around 4.9 to 5.6 percent in published cohorts, compared with a target range of 8 to 11 percent that has been proposed for future trials. Those proposed targets are a research concept, not a medical goal for everyone, and they are one example of why fish oil results can look so different from study to study. Many trials enrolled people without checking whether their levels were low to begin with, so some participants may already have had enough.

What the VITAL trial found

The VITamin D and OmegA-3 TriaL, known as VITAL, is one of the most important studies in this field because it was large, randomized, placebo-controlled, and tested a dose close to what many people actually take. It enrolled 25,871 men aged 50 or older and women aged 55 or older who did not have known cardiovascular disease or cancer, including 5,106 African American participants. Half were assigned to fish oil capsules providing 1 gram a day, which contained 840 milligrams of omega-3 fats, including 460 milligrams of EPA and 380 milligrams of DHA. The other half received a placebo. The trial also separately tested vitamin D3, and I cover that part of the research in my article on vitamin D3 with K2.

After a median of 5.3 years, the primary outcomes did not differ. A major cardiovascular event, which meant a heart attack, stroke, or cardiovascular death, occurred in 805 participants, with a hazard ratio of 0.92 and a 95 percent confidence interval of 0.80 to 1.06. Because that interval includes 1.0, the result is not considered statistically significant. Invasive cancer was found in 1,617 participants, with a hazard ratio of 1.03. Deaths from all causes were also unchanged, with a hazard ratio of 1.02.

The secondary results were more interesting. Total heart attacks were lower in the fish oil group, with a hazard ratio of 0.72 and an interval of 0.59 to 0.90, which is roughly a 28 percent difference. Stroke, with a hazard ratio of 1.04, and cardiovascular death, with 0.96, showed no clear change. The investigators also noticed a possible reduction in the main cardiovascular outcome among participants who reported eating little fish, but they labeled that finding hypothesis-generating, meaning it needs to be confirmed before anyone relies on it. They reported no significant increase in major bleeding or other serious side effects.

One detail helps explain the pattern. The participants began with an average plasma omega-3 index of about 2.67 percent, and after one year it had risen to about 4.13 percent in the fish oil group, a 54.7 percent increase. That is a meaningful change in blood levels, but it also shows that the dose was moderate, and it leaves open the question of whether a larger change would behave differently.

What combining the big trials shows

A single trial can miss a modest effect, so researchers pool trials. Three pooled analyses are especially useful, and they reach different conclusions in a way that is worth understanding.

The first, published in JAMA Cardiology in 2018 by Aung and colleagues, combined 10 large trials in 77,917 people who were at high cardiovascular risk. The trials lasted an average of 4.4 years, and the EPA dose ranged from 226 to 1,800 milligrams a day. Across more than 6,000 coronary heart disease events and 12,001 major vascular events, supplements were not significantly associated with coronary heart disease death (rate ratio 0.93), nonfatal heart attack (0.97), or major vascular events (0.97, with an interval of 0.93 to 1.01). The pattern did not change in subgroups such as people with prior coronary disease, diabetes, or statin use. The authors concluded that the data did not support using these supplements for that purpose.

The second, published in the Journal of the American Heart Association in 2019 by Hu, Hu, and Manson, added three newer large trials and pooled 13 trials in total. When the analysts left out the REDUCE-IT trial, which used a very high dose of a purified EPA product, supplements were associated with an 8 percent lower risk of heart attack (rate ratio 0.92), an 8 percent lower risk of coronary heart disease death (0.92), a 5 percent lower risk of total coronary heart disease events (0.95), and a 3 percent lower risk of total cardiovascular disease (0.97, with an interval of 0.94 to 0.99). There was no significant effect on stroke, with a rate ratio of 1.05. Their analysis also suggested a dose relationship, in which, with REDUCE-IT left out, each additional 1,000 milligrams a day was associated with a 17 percent lower risk of total cardiovascular events, with a wide interval of 4 to 29 percent. Including REDUCE-IT strengthened the results but also introduced significant statistical heterogeneity, which means the trials disagreed with each other more than chance would predict.

The third is the Cochrane review by Abdelhamid and colleagues, updated in 2020. This is the largest assessment, covering 86 randomized trials and 162,796 participants, 28 of which had a low risk of bias. For EPA and DHA, the reviewers found high-certainty evidence of little or no effect on all-cause mortality (risk ratio 0.97, interval 0.93 to 1.01) and on cardiovascular events (0.96, interval 0.92 to 1.01). They found moderate-certainty evidence of little or no effect on stroke (1.02), and low-certainty evidence of little or no effect on arrhythmia (0.99). They also found a small reduction in cardiovascular mortality (0.92, interval 0.86 to 0.99) and low-certainty evidence of a slight reduction in coronary heart disease deaths (0.90) and coronary heart disease events (0.91, interval 0.85 to 0.97). The authors expressed this as roughly one fewer coronary event for every 167 people supplementing for a year or more, and they graded the evidence as low certainty. Plant-based ALA made little or no difference to overall mortality, although it showed a possible small reduction in arrhythmia in two trials.

Why do these three analyses read so differently? Part of the answer is which trials were included, how heavily REDUCE-IT is weighted, and how each team chose to summarize the data. The Aung analysis restricted itself to people at high risk, the Hu analysis looked at dose, and the Cochrane review included many smaller trials and trials of dietary advice. A fair reading is that fish oil at common doses probably has, at most, a small effect on coronary events, and little or no effect on stroke or total mortality.

Why dose and the form of the supplement may matter

If the trial results seem disappointing, one explanation is that the supplements used in many trials did not raise blood levels as much as the researchers assumed. Dr. von Schacky has pointed out that the way EPA and DHA are chemically bound affects absorption, with the order from best to worst being phospholipids, recombined triglycerides, natural triglycerides, free fatty acids, and ethyl esters. He estimates that the chemical form changes absorption by about a factor of two, that eating the capsule with a meal containing fat can change it by up to a factor of 13, and that the formulation technology can change it by up to a factor of 21. He also notes that participants in several large trials were told to take ethyl ester capsules with breakfast, which in many countries is a low-fat meal.

This is an argument made by one research group and should be read as such, but it is plausible and consistent with how fat-soluble nutrients behave. It is also why a practical suggestion you will often hear, to take fish oil with a meal that contains some fat, is reasonable even though trial data on the topic are limited. The broader lesson is that two products listing the same milligrams on the label may not produce the same blood levels.

What the research shows for triglycerides

The clearest and most consistent effect of EPA and DHA is on blood triglycerides, and it depends strongly on dose. The Cochrane review concluded, with high certainty, that increasing long-chain omega-3 intake lowered triglycerides by about 15 percent in a dose-dependent way.

A smaller controlled trial by Skulas-Ray and colleagues shows what that dose dependence can look like. Twenty-six adults with moderately high triglycerides, between 150 and 500 milligrams per deciliter, each took a placebo, a low dose of 0.85 grams a day of EPA plus DHA, and a high dose of 3.4 grams a day, in random order, with six-week breaks between each eight-week period. The low dose had no effect on lipids. The high dose lowered triglycerides by 27 percent compared with placebo, from an average of 237 down to 173 milligrams per deciliter. Neither dose changed total, LDL, or HDL cholesterol, blood vessel function, or inflammatory markers over those eight weeks. The authors also noted that high pharmacologic doses of omega-3 can raise LDL cholesterol when triglycerides fall by a large amount, which is one reason lipid changes are best followed with blood tests under a clinician’s guidance.

The practical point is that the doses that lower triglycerides are well above the 250 to 500 milligrams a day that is common in many over-the-counter products. If someone is trying to understand a triglyceride number, that is a conversation to have with a clinician rather than a label to interpret alone.

What the research shows for blood pressure

Omega-3 intake also has a modest effect on blood pressure. A dose-response meta-analysis by Zhang and colleagues in 2022 pooled 71 randomized trials involving 4,973 people, with a median combined EPA and DHA dose of 2.8 grams a day. The relationship was J-shaped overall, meaning the largest effects appeared at moderate doses rather than the highest ones. At 2 grams a day, systolic blood pressure was lower by an average of 2.61 points and diastolic by 1.64 points. At 3 grams a day, the average reductions were 2.61 and 1.80 points. In people who already had high blood pressure, high blood lipids, or were older, the relationship was steeper and closer to a straight line, suggesting that they may respond differently.

A drop of two or three points is small for any one person, but small average shifts can still matter across a population, and it is another reason that researchers see biological plausibility in the heart-related findings. It is also a reminder that these effects were seen at doses of 2 to 3 grams a day, which is roughly two to four times higher than the dose in VITAL.

Safety, side effects, and the atrial fibrillation question

At modest doses, fish oil appears to be well tolerated. In VITAL, there were no significant differences in gastrointestinal symptoms, major bleeding, or other serious side effects compared with placebo. The Cochrane review similarly found little or no effect on serious adverse events. People do commonly report a fishy aftertaste, belching, or an upset stomach, and those problems are often the reason people stop taking it.

The more important safety signal concerns atrial fibrillation, a common irregular heart rhythm. Earlier pooled analyses raised concern that higher-dose omega-3 might increase the risk, and a 2026 meta-analysis led by Abuknesha and colleagues tried to clarify the picture by pooling 35 randomized trials with 114,592 participants who took at least 500 milligrams a day for at least a year. When they divided the trials by dose and baseline risk, only one group showed a significant increase: people at high cardiovascular risk taking more than 1,500 milligrams a day, whose odds of new atrial fibrillation were 43 percent higher (odds ratio 1.43, interval 1.14 to 1.79), which worked out to an absolute difference of about 0.8 percentage points. The other three groups did not show a significant increase, with odds ratios of 1.07 for high risk with a lower dose, 1.06 for lower risk with a lower dose, and 1.03 for lower risk with a higher dose.

The authors suggest that omega-3 intake slows the resting heart rate through increased vagal tone, and that at high doses in people who already have structural heart disease or take medicines that slow the heart, that effect might tip the balance toward an irregular rhythm. That mechanism is a hypothesis. What is established is the pattern in the trial data, and it is a good reason that high-dose omega-3 products belong under medical supervision.

The question of bleeding deserves its own mention, because many people are told to stop fish oil before surgery. The concern comes from the effect of EPA and DHA on platelets that I described above. In the OPERA trial, analyzed by Akintoye and colleagues, 1,516 people having heart surgery were randomized to fish oil or placebo. The fish oil group took 8 to 10 grams over two to five days before surgery and 2 grams a day afterward, which is an unusually large amount. Major bleeding occurred in 6.1 percent of participants overall, and it was not higher with fish oil (odds ratio 0.81, interval 0.53 to 1.24). The fish oil group also received fewer blood transfusions, with an average of 1.61 units compared with 1.92 units. This was a single trial in a specific population, so it does not settle the question for every procedure, but it does suggest that the long-held advice may deserve a fresh look. The decision about whether to pause a supplement before a procedure still belongs to the surgical team.

Fish oil and type 2 diabetes risk

People sometimes ask whether fish oil changes the chance of developing type 2 diabetes. A systematic review by Wu and colleagues pooled 16 prospective studies covering 18 cohorts, 540,184 people, and 25,670 new cases of diabetes. Eating fish or seafood was not significantly associated with diabetes (relative risk 1.12 per 100 grams a day, interval 0.94 to 1.34), nor was EPA and DHA intake (1.04 per 250 milligrams a day, interval 0.97 to 1.10). Plant ALA showed a non-significant trend toward lower risk (0.93 per 0.5 grams a day). The authors concluded that the findings did not support either major harm or major benefit. These were observational studies, which cannot prove cause and effect, and the results varied considerably from study to study.

Who may benefit from a fish oil supplement

Pulling the evidence together, a few groups are more likely than others to have a reason to consider it. People who rarely eat fish or seafood are the first group, since they start with lower intake and, as in the VITAL subgroup finding, may be the ones for whom the extra EPA and DHA matters most, although that finding needs confirmation. People who follow a plant-based diet may also fall into this group, and some supplements are made from algae rather than fish. People with high triglycerides have the strongest evidence for a measurable effect, but the doses involved are high enough that they should be chosen and monitored by a clinician. People with high blood pressure may see a small additional benefit at doses of 2 to 3 grams a day, again as part of a plan with their own clinician.

For the average healthy person who already eats oily fish once or twice a week, the research gives little reason to expect a large added benefit from a capsule. Dietary guidelines commonly suggest oily fish about twice a week, although the Cochrane authors noted that randomized trial evidence on eating fish itself is limited. If you are unsure where you stand, a blood test of your Omega-3 Index can show how your intake translates into levels. My article on the omega-6 to omega-3 ratio explains related markers, and my guide on how to know which supplements you need offers a broader framework.

Interactions and cautions

A few cautions are worth knowing. Because EPA and DHA can influence platelet function, people who take blood thinners or antiplatelet medicines, or who have a bleeding disorder, should ask their prescriber before using a supplement, even though trials in general populations did not show a significant increase in bleeding. Anyone with a history of atrial fibrillation or other rhythm problems should also discuss doses above 1,500 milligrams a day before starting, given the 2026 pooled results. Because omega-3 intake can lower blood pressure slightly, people on blood pressure medicines may want their readings monitored. People with a fish or shellfish allergy should read labels carefully and ask their clinician which sources are appropriate. Pregnant and nursing women, and anyone preparing for surgery, should make the decision with their own clinician, and the same applies to children.

It also helps to remember that a supplement label gives the total fish oil per capsule, which is often much larger than the amount of EPA and DHA it contains. The EPA and DHA figures on the supplement facts panel are the ones that matter when comparing a product with the doses used in research. For a wider look at whether you need supplements at all, you may find my article on whether you need a multivitamin useful.

The limits of the evidence

The evidence on omega-3 supplements has real limitations. Most large trials tested one fixed dose of one product, which makes it hard to know whether other doses or forms would behave differently. Participants frequently ate fish already and often took other medicines, including statins, which may reduce room for improvement. Many trials did not measure baseline blood levels or check whether levels actually rose. Trials of purified EPA and trials of mixed EPA and DHA are different interventions and should not be regarded as interchangeable. Several of the most interesting findings, including the VITAL subgroup results and the dose-response analyses, are secondary or exploratory and can be confirmed only by future trials. Pooled analyses also depend on which trials the authors choose to include, as the contrast between the three analyses above shows.

Finally, this article focused on cardiovascular risk factors, triglycerides, blood pressure, bleeding, and diabetes risk. Omega-3s have been studied in many other areas, including pregnancy, eye health, mood, and brain function, and the evidence in each of those areas is separate and not covered here.

What is reasonably clear is that EPA and DHA are essential building blocks of cell membranes, that high doses lower triglycerides reliably, that modest doses probably have a small effect on coronary events at most, and that very high doses carry a rhythm risk for some people. What remains uncertain is whether specific forms, doses, or target blood levels would change the heart-related results, and which individuals are most likely to gain from supplementing.

Frequently asked questions

Does fish oil lower the risk of a heart attack?

The results are mixed. In VITAL, heart attacks were 28 percent lower in the fish oil group, but the main outcome of major cardiovascular events did not change significantly. A pooled analysis of 13 trials found about an 8 percent lower rate of heart attacks, while a pooled analysis of 10 trials in high-risk people found no significant association, and the Cochrane review found a small possible reduction in coronary events with low certainty.

How much EPA and DHA do the studies use?

It varies widely. VITAL used 840 milligrams a day of omega-3 fats, with 460 milligrams of EPA and 380 milligrams of DHA. Studies of triglycerides and blood pressure typically used 2 to 3.4 grams a day, and the trials in the atrial fibrillation analysis used at least 500 milligrams a day.

Should I take fish oil with food?

Researchers believe that taking omega-3 capsules with a meal that contains fat improves absorption, and some argue this affected trial results, although trials directly comparing these approaches are limited. Taking capsules with a meal is also the easiest way to reduce stomach upset.

Is fish oil safe to take with blood thinners?

That is a question for the clinician who prescribes your medicine. The OPERA trial and VITAL did not find increased major bleeding with fish oil, but EPA and DHA do act on platelets, and people on blood thinners were not the main focus of those studies.

Is eating fish better than taking a supplement?

The trials do not answer this directly. The Cochrane authors found little evidence from randomized trials about eating fish specifically, and fish also supplies protein and other nutrients. For most people, regular servings of oily fish are a sensible foundation, and a supplement is an additional decision rather than a replacement.

Fish oil is a good example of why a single headline rarely tells the whole story. The fats themselves are real and biologically active, the effect on triglycerides is dependable at higher doses, and the heart-related findings are smaller and less consistent than the marketing around them. A food-first approach, a clear understanding of your own intake and medicines, and a conversation with a clinician about dose are a steadier path than taking a capsule out of habit.

Want a free supplement review?

Send me a list of the vitamins and supplements you take now, or a plan you built yourself or with ChatGPT, and I’ll look it over for free. There is no cost and no appointment, and you’ll hear back from me within about 48 hours.

Get my free supplement review

Sources

Manson JE, Cook NR, Lee IM, et al. VITAL trial of marine n-3 fatty acids (1 g a day) and the risk of cardiovascular disease and cancer in 25,871 adults. New England Journal of Medicine. 2019;380:23-32. Free full text on PubMed Central.

Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals. JAMA Cardiology. 2018;3(3):225-234. Free full text on PubMed Central.

Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127,477 participants. Journal of the American Heart Association. 2019;8:e013543. Free full text on PubMed Central.

Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for cardiovascular disease: Cochrane systematic review update of 86 trials. Cochrane Database of Systematic Reviews. 2020;3:CD003177. Free full text on PubMed Central.

Abuknesha NR, O’Keefe JH, Qian F, et al. Omega-3 fatty acids and risk for atrial fibrillation: an updated meta-analysis of 35 trials including 114,592 individuals. Circulation: Arrhythmia and Electrophysiology. 2026;e014785. Free full text on PubMed Central.

Zhang X, Ritonja JA, Zhou N, Chen BE, Li X. Omega-3 polyunsaturated fatty acids intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2022;11:e025071. Free full text on PubMed Central.

Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. American Journal of Clinical Nutrition. 2011;93(2):243-252. Free full text on PubMed Central.

Akintoye E, Sethi P, Harris WS, et al. Fish oil and perioperative bleeding: insights from the OPERA randomized trial. Circulation: Cardiovascular Quality and Outcomes. 2018;11:e004584. Free full text on PubMed Central.

von Schacky C. Omega-3 index and cardiovascular health. Nutrients. 2014;6(2):799-814. Free full text on PubMed Central.

Wu JH, Micha R, Imamura F, et al. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. British Journal of Nutrition. 2012;107(Suppl 2):S214-S227. Free full text on PubMed Central.

This article is for educational purposes only and is not medical advice. It does not replace an individual evaluation. Talk with your healthcare provider before making changes to your diet, exercise, supplements, or medications, especially if you are pregnant or nursing, or are managing a health condition such as kidney disease, heart disease, or high blood pressure, or if you take prescription medicines.

Looking for practitioner-grade options?

The catalog carries third-party-tested, practitioner-grade supplements from brands Dr. Kneessi uses in practice.

See practitioner-grade options in the catalogNot sure what fits? Take the Supplement Quiz →

Table of Contents

Picture of Dr. Ryan Kneessi, ND

Dr. Ryan Kneessi, ND

Dr. Ryan Kneessi, ND, is a naturopathic doctor in Odenton, Maryland, who practices functional medicine.

Disclosure: I earn a margin on some products purchased through my Fullscript store, and I only recommend products I would use in my own practice.

Free Supplement Quiz
Answer a few questions to see which supplement types may fit your goals, plus safety notes to review.
Take the Supplement Match QuizShop My Fullscript Store